Compare Biogen Inc (BIIB) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SkyWest Inc — how do they compare? Biogen Inc trades at $207.3 (market cap $30.13B), while SkyWest Inc trades at $107.53 (market cap $4.19B). The key difference: Biogen Inc is far larger — about 7.2× SkyWest Inc's market cap, and Biogen Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | SKYW | |
|---|---|---|
Market Cap | $30.13B | $4.19B |
Sector | Health | Technology |
52-Week High | $216.63 | $123.72 |
52-Week Low | $128.93 | $78.40 |
Enterprise Value | $37.20B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
SkyWest (SKYW) trades at $106.38, down 1.2% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $109.33. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales alongside institutional interest and a 7.7% post-earnings rally noted by Zacks Investment Research on 2026-07-27.
The outlook is cautiously positive given analyst buy ratings (56.25%) and undervalued metrics, but risks include fuel cost volatility from Iran war impacts (New York Post, 2026-07-07) and mixed earnings performance. Upside potential exists if Q3 2026 meets its $3.13 EPS expectation, balancing insider selling with buyback support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
